Professor Philip Conaghan is joined by Professor Chris Edwards and Dr Marwan Bukhari. Together they describe the burden of disease experienced by patients with moderate RA and review the recommended assessments employed to identity patients with moderate RA that determine those who are suitable for advanced therapies. They also discuss the role of advanced therapies in the management of this patient group and highlight the importance of holistic patient-centred care. Concluding the webinar, the faculty discuss a case study of difficult-to-treat moderate RA, discussing the options available at each stage of the patient journey
This was a live webinar from November 2021 and is available now to watch on demand.
Jobcode: UK-RA-NA-202112-00001 March 2022
Professor Phil Conaghan
Professor Conaghan is Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine (a EULAR Centre of Excellence) at the University of Leeds and Deputy Director of the NIHR Leeds Biomedical Research Centre, UK. His research focuses on understanding pathogenesis and developing effective therapies for people with common arthritides. He is an executive member of the international outcomes group OMERACT, is co-editor of the Oxford Textbook of Rheumatology and has authored over 600 publications. In 2021 he received the international Carol Nachman award for Rheumatology.
Professor Christopher Edwards
Professor Edwards is a Consultant Rheumatologist and Co-Director of the NIHR Southampton Clinical Research Facility within the University Hospital Southampton NHS Foundation Trust (UHS). Professor Edwards has been an investigator on numerous clinical trials of therapies for inflammatory rheumatic diseases. As Co-Director, he is engaged with translational research at the NIHR Southampton Clinical Research Facility. He is also Clinical Director of the Southampton Musculoskeletal Research Unit, a recognised EULAR centre of excellence and is the Chair of the EULAR Education Committee.
Dr Marwan Bukhari
Dr Marwan Bukhari is a Consultant Rheumatologist at University Hospitals of Morecambe Bay NHS Trust and an Honorary Senior Lecturer at Manchester University. His clinical base is at the Royal Lancaster Infirmary where is also Director of Medical Education and Academic Foundation tutor. His research interests include inflammatory arthritis and quality of life in patients with arthritis and osteoporosis. Dr Bukhari is also the editor in chief of the journal Rheumatology (Oxford). He is the northern regional advisor for NRAS and the North West Coast Musculoskeletal NIHR lead.
Listen to our podcast Optimising RA patient care through rheumatology service development with Dr Toby Garrood, Kalveer Flora and Ruth Slack
UK-RA-NA-202202-00015 | Date of preparation March 2023
Adverse events should be reported.
For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store).
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.
Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
© 2022 Galapagos NV. All rights reserved.
GB-IBD-FIL-202208-00005 |
Date of preparation: October 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
© Copyright 2021 Galapagos NV
This link will take you away from the Galapagos website and you will be re-directed to a non-Galapagos website. Galapagos does not accept liability for sites controlled by third-parties.
*By choosing the "Healthcare Professional" option, you affirm your status as a healthcare professional in the UK and Ireland and acknowledge that you will receive promotional information pertaining to prescription-only medicines.